NovoCure Limited (FRA:038)

Market Cap	1.24B -25.5%
Revenue (ttm)	558.16M +8.3%
Net Income	-116.02M
EPS	-1.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	25
Open	10.47
Previous Close	10.75
Day's Range	10.47 - 10.47
52-Week Range	8.12 - 16.72
Beta	n/a
RSI	60.41
Earnings Date	Apr 30, 2026

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2000
• Employees: 1,605
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 038

Financial Performance

In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.

Financial numbers in USD